Dr. Knoche is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5225 Mid America Plz
# Dv
Saint Louis, MO 63129Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2011 - 2014- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
- Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
MO State Medical License 2009 - 2025
Publications & Presentations
PubMed
- 16 citationsSurvival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.Martin W Schoen, Kenneth R Carson, Seth A Eisen, Charles L Bennett, Suhong Luo
Prostate Cancer and Prostatic Diseases. 2023-12-01 - 25 citationsConcomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.Amy Zhou, Eric M. Knoche, Elizabeth K. Engle, Daniel A.C. Fisher, Stephen T. Oh
Blood Cancer Journal. 2015-10-02 - 40 citationsImmunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancerDhruv Bansal, Melissa A. Reimers, Eric M. Knoche, Russell K. Pachynski
Cancers. 2021-01-18
Press Mentions
Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced CancerApril 18th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
